MedTrace Logo

Effect of Simvastatin on Pneumonia Prognosis in Elderly Patients

NCT01651728 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2012-08-06

No results posted yet for this study

Summary

The objective is to assess the effect of simvastatin on immunology, inflammatory, and coagulation responses, and mortality in elderly with pneumonia based. The primary outcome is mortality event.

The hypothesis of this study is that simvastatin therapy will reduce mortality in elderly with pneumonia.

Conditions

  • Community-Acquired Pneumonia

Interventions

DRUG

Simvastatin

Tablet 20 mg once daily for 30 days

DRUG

Placebo

daily for 30 days

Sponsors & Collaborators

  • Indonesia University

    lead OTHER

Principal Investigators

  • Kuntjoro Harimurti, MD, MSc · Department of Internal Medicine, Cipto Mangunkusumo Hospital, Faculty of Medicine University of Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-08-31
Completion
2013-09-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01651728 on ClinicalTrials.gov